Level Up Your Nucleic Acid-Based Therapy

Building labs and capital assets for bioprocesses is both cost and labor intensive. To streamline the development of next-gen nucleic acid-based therapies, we unite and improve every component – processes, scale-up, raw material supplies, analytics and GMP strategy.

The end result — a network of high-performance facilities and digitally interconnected processes that we are building to help you reliably scale up production and meet demand.

Our aim is to help you save time and manufacturing costs by providing access to world-class expertise and modular biomanufacturing capabilities at all scales.